Ausgabe 10/2018
Inhalt (13 Artikel)
Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math
Frank A. Giordano, Marlon R. Veldwijk, Carsten Herskind, Frederik Wenz
Early versus late prophylactic cranial irradiation in patients with extensive small cell lung cancer
Yi Chen, Jinyu Li, Yibao Zhang, Yi Hu, Guoqing Zhang, Xiang Yan, Zhi Lin, Zhifei Zhao, Shunchang Jiao
Prognostic factors in stereotactic body radiotherapy of lung metastases
K. J. Borm, M. Oechsner, K. Schiller, J. C. Peeken, H. Dapper, S. Münch, L. Kroll, S. E. Combs, M. N. Duma
Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients
Chai Hong Rim, Won Sup Yoon, Jung Ae Lee, Dae Sik Yang, Nam Kwon Lee, Young Je Park, Chul Yong Kim
Complementary medicine in radiation oncology
Kerstin A. Kessel, Evelyn Klein, Carolin C. Hack, Stephanie E. Combs
Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial)
Tanja Sprave, Vivek Verma, Robert Förster, Ingmar Schlampp, Thomas Bruckner, Tilman Bostel, Stefan Ezechiel Welte, Eric Tonndorf-Martini, Rami El Shafie, Nils Henrik Nicolay, Jürgen Debus, Harald Rief
Automatic replanning of VMAT plans for different treatment machines: A template-based approach using constrained optimization
Luise A. Künzel, Oliver S. Dohm, Markus Alber, Daniel Zips, Daniela Thorwarth
Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™
Markus Wösle, Lothar Krause, Shanthala Sreenivasa, Dirk Vordermark, Ilja F. Ciernik
MRI-based high-precision irradiation in an orthotopic pancreatic tumor mouse model
S. Dobiasch, S. Kampfer, D. Habermehl, M. N. Duma, K. Felix, A. Strauss, D. Schilling, J. J. Wilkens, S. E. Combs
Die Radiotherapie des Pleuramesothelioms – Klinische Praxisleitlinie der American Society of Clinical Oncology
Christoph Süß, Oliver Kölbl
Besseres Gesamtüberleben durch Brachytherapie beim Endometriumkarzinom im Stadium III
Peter Niehoff
Hochrisiko-Endometriumkarzinom: Immer eine adjuvante Radiochemotherapie?
Felix Bock, Guido Hildebrandt